Pharma and biotech

World-class attractiveness

Western Switzerland’s Health Valley is ranked just behind Cambridge and in front of most European regions with regard to its attractiveness, which is why large multinational companies such as Merck, UCB, Takeda (formerly Baxter)
and CSL Behring chosen the region as the location for their production sites, some of the most advanced in the world.  Furthermore, the Swiss life sciences sector has the highest productivity per employee in international surveys.

Excellent infrastructure

Technology and innovation parks, research centers, labs, equipment:  the Greater Geneva Bern area has the advanced infrastructure necessary for companies in the life sciences sector to develop their activities. Campus Biotech in Geneva is a center of excellence for research in biotechnology
and life sciences, as is Biopôle in Lausanne, specializing in oncology, immunology, medtech, personalized medicine, nutrition and digital health.  In Valais, BioArk supports SMEs and start-ups in transforming their projects into industrial and commercial reality and in developing their business. The GGBa also relies on the expertise of the BioAlps platform.

Key figures from the pharma and biotech sectors

  • 4 times more productive than the entirety of the Swiss economy
  • 59.9 billion CHF in gross value added
  • 97.6 billion CHF in exports
  • 47,500 employees

Source: Interpharma (2019-2020)

No. 1 in life sciences

SIX Swiss Exchange is among the leading European stock exchanges and is ranked first in the field of life sciences.  Approximately 40% of the capital of European life sciences companies is traded there, which is a reflection of Switzerland’s historical ties with the sector. Switzerland has the world’s highest per capita density of bio and medtech companies.

This website uses cookies to improve user experience. More information